Admp - Pagina 19
Tracollo finale di Intesa Sanpaolo (-7,5%), è buio pesto per le banche del Ftse Mib con Unicredit ai minimi storici
Chiusura di ottava con il segno meno per Piazza Affari che paga l?andamento negativo di Wall Street dopo le payrolls Usa peggiori delle attese e la debacle di alcune delle …
Crollo occupazione USA e il peggio deve ancora arrivare, la vera incognita è quanto durerà la crisi
Il coronavirus mette fine a quasi 10 anni di crescita incessante dell'occupazione negli Stati Uniti. A marzo la prima economia mondiale ha visto bruciare migliaia di posti di lavoro a …
Coronavirus ed Europa: la proposta di Cottarelli, Galli e Letta per battere ‘crisi più violenta di quella del 2008’
"La crisi in corso è più violenta di quella del 2008": inizia così l'articolo "Come raggiungere un accordo dell'Eurogruppo", che porta la firma di Carlo Cottarelli, Giampaolo Galli e Enrico …
Tutti gli articoli
Tutti gli articoli Tutte le notizie

  1. #181

    Data Registrazione
    Feb 2016
    Messaggi
    1,433
    Mentioned
    6 Post(s)
    Quoted
    689 Post(s)
    Potenza rep
    42949677
    Citazione Originariamente Scritto da Salva_Tori Visualizza Messaggio
    ADMP direi anche questa in partenza
    Ha chiuso a 0,96 ...aspettando il Q e non solo...

    Vediamo nei prossimi giorni

  2. #182
    L'avatar di serenella6
    Data Registrazione
    May 2009
    Messaggi
    9,243
    Mentioned
    0 Post(s)
    Quoted
    155 Post(s)
    Potenza rep
    42949683
    Citazione Originariamente Scritto da Salva_Tori Visualizza Messaggio
    ADMP direi anche questa in partenza
    Si..l'avevo scritto qualche giorno fa da tenere in vista!

  3. #183

  4. #184
    L'avatar di Salva_Tori
    Data Registrazione
    Jun 2007
    Messaggi
    9,231
    Mentioned
    0 Post(s)
    Quoted
    530 Post(s)
    Potenza rep
    42949685
    SAN DIEGO, Nov. 12, 2019 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (ADMP) today announced financial results for the third quarter ended September 30, 2019 and provided a business update.

    Dr. Dennis J. Carlo, President and Chief Executive Officer of Adamis Pharmaceuticals, stated, “Since the full launch in July, Sandoz has implemented several initiatives that we expect will increase sales of SYMJEPITM. We believe the Sandoz team is now targeting allergists and primary care physicians with their retail launch. A new website was launched in the third quarter that provides patients and physicians with product information, instructions for use and provides links to order demonstrator devices and to have SYMJEPI shipped to patients’ homes through PillPack, an Amazon company.”
    “While we are eager for sales of SYMJEPI to grow, we are also looking forward to a final decision by the FDA on ZIMHITM, our naloxone injection product candidate. If approved, we believe our company will be very well positioned for growth in 2020 as we plan to play an important role in combating the ongoing public health crisis of opioid overdose.”
    Product Updates
    SYMJEPI (epinephrine) Injection
    During the third quarter, Adamis’ commercial partner, Sandoz, announced the full launch of our SYMJEPI epinephrine injection product, making both the 0.3mg and 0.15mg doses available in local pharmacies across the U.S. Sandoz increased and continues to expand its commercial initiatives and we expect those efforts to begin translating into a steeper sales growth during the fourth quarter.
    In addition to the U.S., Adamis continues to seek opportunities to market SYMJEPI into other territories and on October 1, 2019, the company announced it had entered into an exclusive distribution and commercialization agreement with Emerge Health to seek registration and commercialize SYMJEPI in Australia and New Zealand.
    ZIMHI (naloxone) Injection
    Since Adamis’ November 4, 2019 update, the U.S. Food and Drug Administration (“FDA”) continues to review the company’s New Drug Application (NDA) for its ZIMHI high-dose naloxone product candidate, and as of the date of this press release the company has not received any notice of action from the FDA. The company believes that if approved, ZIMHI could be an important part of the solution to this growing health crisis of opioid overdose. The company believes that discussions with potential partners for ZIMHI have sufficiently progressed and that while no assurances are possible, the company expects to be able to announce a commercial partner soon after receiving clearance from the FDA.
    Drug Outsourcing Facility
    During the third quarter of 2019, the company’s wholly owned drug outsourcing facility, US Compounding (USC), continued to grow its revenues by approximately 19% in the third quarter compared to the same quarter last year and approximately 25% year-to-date versus the same nine months of 2018. USC’s increase in revenues was due to the increase in sales of USC’s sterile pharmaceutical formulations resulting in part from an increase in production capacity in order to meet product demand and from marketing personnel efforts.
    Third Quarter 2019 Financial Results
    Revenues increased approximately 54%, from $3.8 million to $5.9 million, for the three months ended September 30, 2018 and 2019, respectively. Revenues increased by approximately 52%, from $10.9 million to $16.6 million for the first nine months of 2018 compared to the same period in 2019. The increase was primarily attributable to growth in sales of USC’s sterile pharmaceutical products and revenue relating to SYMJEPI.
    Selling, general and administrative expenses (“SG&A”) decreased approximately 19%, from $6.5 million to $5.3 million for the three months ended September 30, 2018 and 2019, respectively. The decrease in SG&A expenses was primarily due to decreases in wages and benefits.
    Research and development expenses (“R&D”) decreased approximately 15%, from $3.9 million to $3.3 million for the third quarter of 2018 compared to the same period in 2019. The decrease was primarily due to a decrease in development costs of our product candidates. We anticipate that R&D expenses will continue to decrease in the fourth quarter of 2019.

  5. #185
    L'avatar di andrealor
    Data Registrazione
    May 2015
    Messaggi
    786
    Mentioned
    0 Post(s)
    Quoted
    281 Post(s)
    Potenza rep
    4448109
    bene ma non benissimo

    in after-hours ha perso il 2%

    ancora 12M$ in cassa
    Cash and equivalents at the end of the third quarter was approximately $12.1 million.

  6. #186

    Data Registrazione
    Feb 2016
    Messaggi
    1,433
    Mentioned
    6 Post(s)
    Quoted
    689 Post(s)
    Potenza rep
    42949677
    Forse tiene...

  7. #187

  8. #188
    L'avatar di Salva_Tori
    Data Registrazione
    Jun 2007
    Messaggi
    9,231
    Mentioned
    0 Post(s)
    Quoted
    530 Post(s)
    Potenza rep
    42949685
    0.5299 -0.73 (-57.94%) Pre-Market: 8:38AM EST
    men.ghia !

  9. #189
    L'avatar di Gnappo
    Data Registrazione
    Mar 2001
    Messaggi
    3,730
    Mentioned
    1 Post(s)
    Quoted
    185 Post(s)
    Potenza rep
    42949692
    Crl...

  10. #190

Accedi